RhumbLine Advisers
PMVP icon

RhumbLine Advisers’s PMV Pharmaceuticals PMVP Stock Holding History

RhumbLine Advisers’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,035
Closed -$37.3K – 4301
2024
Q2 		$37.3K Sell
23,035
-39,693
-63% -$71.6K ﹤0.01% 3759
2024
Q1 		$107K Buy
62,728
+2,980
+5% +$5.57K ﹤0.01% 3431
2023
Q4 		$185K Sell
59,748
-1,646
-3% -$4.36K ﹤0.01% 3223
2023
Q3 		$377K Buy
61,394
+80
+0.1% +$550 ﹤0.01% 2790
2023
Q2 		$384K Buy
61,314
+3,316
+6% +$17.4K ﹤0.01% 2861
2023
Q1 		$277K Buy
57,998
+1,584
+3% +$11.1K ﹤0.01% 2641
2022
Q4 		$491K Buy
56,414
+755
+1% +$8.05K ﹤0.01% 2470
2022
Q3 		$662K Buy
55,659
+2,838
+5% +$41K ﹤0.01% 2367
2022
Q2 		$753K Buy
52,821
+25,131
+91% +$366K ﹤0.01% 2280
2022
Q1 		$577K Buy
27,690
+1,983
+8% +$35K ﹤0.01% 2358
2021
Q4 		$594K Buy
25,707
+896
+4% +$21.6K ﹤0.01% 2441
2021
Q3 		$739K Buy
24,811
+1,257
+5% +$40.1K ﹤0.01% 2366
2021
Q2 		$805K Buy
23,554
+9,536
+68% +$319K ﹤0.01% 2340
2021
Q1 		$461K Buy
14,018
+90
+0.6% +$3.55K ﹤0.01% 2530
2020
Q4 		$857K Buy
+13,928
New +$546K ﹤0.01% 2211

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's PMVP Position: Q3 2024 in Review

RhumbLine Advisers sold out of PMV Pharmaceuticals (PMVP) in Q3 2024, closing a stake of 23,035 shares — an estimated $37.3K sold.

RhumbLine Advisers first reported a position in PMVP in Q4 2020 and held it in 15 quarters. The position peaked at $857K in Q4 2020. 74 funds tracked by Wall St. Rank hold PMVP as of Q3 2024.

  • RhumbLine Advisers reported no remaining PMV Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 23,035 PMV Pharmaceuticals shares in Q3 2024, an estimated $37.3K.
  • RhumbLine Advisers first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • RhumbLine Advisers's PMV Pharmaceuticals position peaked at $857K in Q4 2020.
  • 74 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.